UTRECHT, The Netherlands--(BUSINESS WIRE)--AM-Pharma B.V. today announced that the first patients have been treated in a Phase 2 clinical study evaluating the company’s proprietary recombinant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback